Equities

Malin Corporation PLC

MLC:ISE

Malin Corporation PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)5.60
  • Today's Change0.20 / 3.70%
  • Shares traded29.54k
  • 1 Year change+8.74%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Malin Corporation PLC is focused on investing in life sciences companies. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. It is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR0.00
  • Incorporated2014
  • Employees3.00
  • Location
    Malin Corporation PLCThe Lennox Building50 Richmond Street SouthDUBLIN D02 FK02IrelandIRL
  • Phone+353 19015700
  • Fax+353 19015701
  • Websitehttp://malinplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
XSpray Pharma AB (publ)0.00-15.43m90.02m26.00--1.89-----7.02-7.020.0022.190.00----0.00-26.60-18.38-28.03-19.26--------4.36--0.0504-------36.45--2.87--
Haemato AG260.81m9.61m90.99m78.009.450.60688.450.34891.841.8450.1028.671.479.8012.483,343,690.005.412.016.452.707.568.423.681.211.66--0.0203157.20-12.95-3.0325.393.32-5.75-16.74
Cereno Scientific AB0.00-4.13m91.35m5.00--4.09-----0.241-0.2410.000.92580.00----0.00-19.22-16.81-20.75-18.26-----------12.920.1734-------73.95--44.79--
Diamyd Medical AB24.22k-10.32m97.20m26.00--5.85--4,013.92-1.41-1.410.00331.910.0014--6.5611,280.00-59.77-25.46-66.19-28.37-4,930.85-1,419.23-42,617.73-5,896.43---130.780.1176--20.26-5.54-12.13------
Infant Bacterial Therapeutics AB0.00-10.57m98.82m8.00--3.90-----9.90-9.900.0022.650.00----0.00-35.11-16.11-38.65-16.69------------0.00-------88.03------
Scancell Holdings Plc0.00-13.20m99.01m51.00---------0.0138-0.01380.00-0.01020.00----0.00-37.31-33.32-40.52-35.82-------817.98----1.73-------161.24--77.85--
SyntheticMR AB (publ)7.66m859.60k100.24m37.00114.5210.0071.8113.080.24450.24452.172.800.6599--1.612,411,162.007.417.198.898.85105.78106.7411.229.08--14.130.010721.5030.6713.0570.34-7.3326.79--
Scope Fluidics SA119.29k-4.34m102.34m40.00--5.47--857.93-6.89-6.890.189329.690.00232.730.182712,900.00-8.3952.74-8.6157.32-265.89-420.87-3,640.5030,134.7814.60--0.0289--27.72---105.76--89.99--
AB Science SA777.00k-16.89m102.58m89.00------132.02-0.3561-0.35610.0164-0.38790.02840.3942.507,471.15-61.64-70.81-237.22-316.6388.1691.37-2,173.10-1,225.491.41--135.44---40.39-11.245.86--5.07--
Malin Corporation plc0.000.00105.31m3.00--0.9702526.56---0.0154-0.01540.005.770.00----0.000.007.090.007.66------273.93----0.000.00-----100.00------
Maat Pharma SA2.23m-19.72m109.19m50.00--5.34--49.01-1.73-1.730.1961.760.05084.844.1644,560.00-44.99-35.49-58.93-42.9874.28---884.96-1,157.542.76-49.610.4075--55.80---43.78--30.30--
Eurofins-Cerep SA46.17m9.21m109.96m233.0011.941.839.822.381,826.411,826.419,160.0011,939.290.68141.666.04220,892.0013.6015.1916.0618.9485.5767.3019.9519.725.17112.420.000050.0014.4514.3017.0924.52----
Medica SpA63.83m3.26m111.49m706.0034.172.2611.481.750.77270.772715.1111.680.58171.075.2290,672.332.26--3.31--58.28--3.88--0.82764.210.3487--16.13---12.52------
Arcticzymes Technologies ASA10.16m1.60m111.65m61.0069.434.2452.0710.990.37020.37022.356.070.36180.59412.43--5.6915.526.1217.1695.0296.6915.7433.1012.43--0.0392---13.1612.24-43.02--47.93--
Turk Ilac Ve Serum Sanayi AS54.99m3.04m114.86m439.0037.803.2528.902.090.65340.653411.827.601.2832.393.394,358,227.007.073.1811.065.5222.4323.445.532.361.201.670.25--16.8881.44229.4749.0037.65--
DBV Technologies SA4.88m-94.22m114.98m88.00--0.7503--23.55-1.00-1.000.05181.590.0209--0.373870,752.81-40.35-64.67-46.22-80.94--91.59-1,929.97-1,345.10----0.0128---15.14-18.452.08---38.41--
Data as of May 02 2024. Currency figures normalised to Malin Corporation PLC's reporting currency: Euro EUR

Institutional shareholders

0.07%Per cent of shares held by top holders
HolderShares% Held
Aviva Investors Global Services Ltd.as of 15 Apr 202113.41k0.07%
Liontrust Portfolio Management Ltd.as of 30 Nov 20190.000.00%
Data from 31 Dec 2023 - 29 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.